

SASTASUNDAR VENTURES LIMITED

Azinganj House, 2nd floor,
7 Abanindra Nath Thakur Sarani (Formerly Camac Street),
Kolkata – 700017, India. Tel: +91 33 2282 9330; Fax: +91 33 2282 9335
Email: info@sastasundar.com; Website: www.sastasundarventures.com
CIN: L65993WB1989PLC047002

Date: 13-11-2025

To
The General Manager
Department of Corporate Services
BSE Limited
Phiroze Jeejeebhoy Tower
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Mumbai - 400 051

Ref: **BSE Scrip Code: 533259; NSE Symbol: SASTASUNDR**

Sub: **Intimation under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Investor Presentation**

Dear Sir/ Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 please find attached herewith the Investor Presentation of the Company.

This is for your information and record.


Thanking you,

Yours faithfully,

For **Sastasundar Ventures Limited**

Pratap Singh
Company Secretary and Compliance Officer

Encl: As Above



SastaSundar
health & happiness

Investor's Update

November 2025

“ SastaSundar operate digital platforms for Pharmacy, Wellness and Diagnostics, providing Accessible, affordable, scalable and sustainable person-centric health care solution ”

This presentation and the accompanying slides (the “Presentation”), which have been prepared by SastaSundar Ventures Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any securities, and shall not form the basis or be relied on in connection with any contract or binding commitment whatsoever. No offering of securities of the Company will be made except by means of a statutory offering document containing detailed information about the Company.

This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

Certain matters discussed in this Presentation may contain statements regarding the Company’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. These risks and uncertainties include, but are not limited to, the performance of the Indian economy and of the economies of various international markets, the performance of the industry in India and world-wide, competition, the Company’s ability to successfully implement its strategy, the Company's future levels of growth and expansion, technological implementation, changes and advancements, changes in revenue, income or cashflows, the Company's market preferences and its exposure to market risks, as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially and adversely from results expressed in or implied by this Presentation. The Company assumes no obligation to update any forward-looking information contained in this Presentation. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third-party statements and projections.

All Maps used in the Presentation are not to scale. All data, information and maps are provided "as is" without warranty or any representation of accuracy, timeliness or completeness.

*When Science meets scale,
When innovation become inclusive,
When technology drives transformation,
The foundation for great achievements is laid.*

Shri Narendra Modi
Hon'ble Prime Minister of India



Our Operations




B2C - Healthcare Digital Platform

Pharmacy

Wellness


Diagnostic



B2B - Healthcare Digital Platform

Pharmacy

Wellness



Accelerating Growth

1. CATEGORY EXPANSION

From: Medicine & Wellness

To:

- Personal Care
- Beauty Care
- Surgical Care
- Nutrition and Nutraceuticals
- Pet care
- Private Label - Generic JITO,
- JITO line of OTC products

2. GEOGRAPHY EXPANSION

From:

- West Bengal
- NCR (National Capital Region)
- Jharkhand
- Assam

To:

- Eastern India - Bihar, Odisha, Chhattisgarh
- Northern India – Uttar Pradesh, Haryana, Rajasthan, Uttarakhand, Madhya Pradesh
- North-East India - to expand in all seven states of North-East (Arunachal Pradesh, Assam, Manipur, Meghalaya, Mizoram, Nagaland, Tripura)

3. CUSTOMER EXPANSION (B2B)

From: Pharmacies

To:

- Hospitals
- Clinics
- Doctor Practice Centres
- Health Centres
- Retailers in new product categories

Accelerating Growth

4. PRODUCT & SERVICE EXPANSION

Product Expansion - B2B

- Private Label Development: Launch of Generic JITO and JITO OTC product lines.
- Value-Added Services:
 - Integrated doctor consultation panel
 - Diagnostic lab booking services
 - On-demand order fulfilment support
 - Insurance POS enablement and exclusive JITO Shop-in-Shop sections

Product Expansion - B2C

- Curated “JITO Recommended” product channel
- JITO-branded medicines and OTC range
- Quick Health Initiative:
 - 10-minute Doctor Consultation
 - 30-minute Medicine Delivery
 - 4-hour Diagnostic Report
 - Comprehensive, home-based healthcare solution

5. CHANNEL EXPANSION

- **Healthbuddy Stores:** Incorporation of Quick Health support facilities.
- **Exclusive JITO Franchise:** Retail distribution of JITO-branded medicines and OTC products.
- **JITO Clinic Model –**
Unified Doctor + Generic Medicine + Diagnostic Collection Centre format: Enhancing affordability (up to 60% savings in time and cost), accessibility, and improved quality and respect

Expanding Fulfilment Centres (FCs)

Strengthening backend capacity to support scalable growth and faster service delivery.

- **West Bengal:** Automation upgrade to *double existing capacity*.
- **Noida:** New FC under implementation - *doubling overall capacity*.
- **Guwahati (Assam):** Under implementation – *expanding regional coverage and capacity*.
- **Lucknow:** *New high-capacity FC* to enhance North India reach.
- **Udaipur:** *New large-capacity FC* strengthening North India operations.

Strategic Investments in Health Startups

Enhancing service capacity through partnerships and innovative healthcare models.

- **Dr. Sudhir Pain Relief Clinic:** Expanding pain management expertise
- **Alexa Health:** Strengthening physiotherapy and home-care reach
- **Diagnoeasy:** Integrating doctor and home-care diagnostic services

AI Integration Across the Value Chain

Embedding AI to improve efficiency, accuracy, and customer experience.

- **Intelligent medicine & diagnostic counselling.**
- **Consultation validation** for quality assurance.
- **Wellness counselling** and personalized recommendations.
- **Smart health records** with automated briefing tools.
- **Backend process automation** to enhance productivity.

Building A Stronger MOAT With Competitive Advantage

1. **Capital Efficient** - Disciplined capital deployment ensuring strong returns and long-term value creation.
2. **Cost Efficiency** - Scalable operating model driving margin resilience and profitability.
3. **Superior Customer Value Proposition** - Delivering differentiated, trusted, and affordable healthcare solutions that build lasting loyalty.
4. **Scalable Supply Chain Integration** - Strengthening pan-India reach — from metros to Tier 2 towns and rural markets.
5. **Human-Tech Ecosystem** - Leveraging technology to enhance human touch, engagement, and service excellence.
6. **Strong Direct Partnerships** - Strategic alliances with reputed pharma companies ensuring reliability and consistent supply.
7. **Motivated & Competent Team** - Empowered leadership and skilled teams driving innovation and operational excellence.
8. **Universal Market Reach** - Inclusive business model serving every income segment across urban and rural India.

Q2 FY26 Consolidated Profit & Loss Statement

Particulars (Rs. Crs)	Q2 FY26	Q2 FY25	Y-o-Y	Q1 FY26	Q-o-Q	H1 FY 25-26	H1 FY 24-25	Y-o-Y
Revenue from Operations	307.9	263.5	16.9%	278.5	10.6%	586.5	526.4	11.4%
Cost of Materials Consumed	285.0	246.4		257.6		542.6	489.1	
Gross Profit	22.9	17.1	34.2%	20.9	9.8%	43.9	37.3	17.7%
GP %	7.5%	6.5%		7.5%		7.5%	7.1%	
Employee Benefits Expense	19.9	11.6		17.3		37.2	22.2	
Other Expenses	19.1	20.3		17.4		36.5	39.6	
EBITDA	(16.0)	(14.8)		(13.8)		(29.8)	(24.6)	
EBITDA %	(5.2%)	(5.6%)		(5.0%)		(5.1%)	(4.7%)	
Other Income [#]	(1.1)	32.3		45.3		44.2	67.5	
Depreciation and Amortisation Expense	1.3	1.5		1.2		2.5	3.1	
EBIT	(18.4)	16.0		30.3		11.8	39.9	
Finance Costs	0.0	0.1		0.1		0.1	0.2	
Exceptional Items	(0.2)	(189.6)		0.0		(0.2)	(188.7)	
PBT	(18.6)	(173.7)		30.2		11.5	(149.0)	
Total Tax Expense/ (Income)	(3.2)	(22.9)		3.6		0.4	(48.7)	
Profit for the period/Year	(15.4)	(150.8)		26.6		11.2	(100.3)	
PAT %	(5.0%)	(57.2%)		9.5%		1.9%	(19.0%)	
Share of profit/(loss) from Associate	0.0	(4.0)		0.0		0.0	(13.0)	
Profit for the period/Year	(15.4)	(154.8)		26.6		11.2	(113.3)	


[#] Other Income includes financial service income

Breakup of Revenue (Vertical)


Particulars (Rs. Crs)	Q2 FY26	Q2 FY25	Q1 FY26	H1 FY26
Supply chain				
SastaSundar	39.4	24.7	33.3	72.7
Retailer Shakti	267.8	238.0	244.5	512.3
Diagnostic	0.7	0.8	0.7	1.4
Healthcare Network	307.9	263.5	278.5	586.4
Financial Services	(1.1)	32.3	19.9	18.8
Total Revenue	306.8	295.8	298.4	605.2

Annual Financial Highlights

Revenue from Operations



Gross Profit



Historical Consolidated Profit & Loss Statement

Particulars (Rs. Crs)	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21
Revenue from Operations	1,088.5	1,355.2	1,036.9	623.0	540.0
Cost of Materials Consumed	1017.4	1232.8	960.4	582.5	492.5
Gross Profit	71.1	122.4	76.5	40.5	47.5
GP %	6.5%	9.0%	7.4%	6.5%	8.8%
Employee Benefits Expense	49.8	49.0	45.3	43.9	29.1
Other Expenses	99.8	88.5	78.0	53.7	40.9
EBITDA	(78.5)	(15.1)	(46.8)	(57.1)	(22.5)
EBITDA %	(7.2%)	(1.1%)	(4.5%)	(9.2%)	(4.2%)
Other Income [#]	82.3	81.0	26.5	20.1	11.6
Depreciation and Amortisation Expense	5.8	9.1	8.2	4.2	4.5
EBIT	(2.0)	56.7	(28.5)	(41.2)	(15.4)
Finance Costs	0.2	1.0	0.9	1.6	1.0
Exceptional Items	(190.6)	0.0	(8.0)	1,157.5	0.0
PBT	(192.9)	55.7	(37.4)	1,114.7	(16.4)
Tax Expense	(70.1)	(36.4)	(22.8)	244.4	0.7
PBT before Share of Associate	(122.7)	92.0	(14.6)	870.3	(17.1)
Share from Associate	(10.8)	(86.2)	(84.9)	(5.2)	0.0
Profit for the year	(133.5)	5.9	(99.5)	865.1	(17.1)
PAT %	(12.3%)	(0.4%)	(9.6%)	138.9%	(3.2%)
EPS	(28.66)	2.79	(22.70)	197.04	(3.27)

[#] Other Income includes financial service income

Historical Consolidated Balance Sheet

Equity & Liabilities (Rs. Crs)	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21
Equity Share Capital	31.8	31.8	31.8	31.8	31.8
Other Equity [#]	832.7	967.7	961.7	1,062.4	197.6
Total Equity	864.5	999.5	993.5	1,094.2	229.4
Non-Financial Liabilities					
(i) Borrowings	0.0	0.0	0.0	0.0	0.0
(ii) Other Financial Liabilities	5.3	3.3	8.2	3.5	1.5
Provisions	7.2	5.4	4.5	2.1	1.9
Tax Liabilities (Net)	5.4	2.6	24.1	17.9	0.0
Deferred Tax Liabilities (Net)	4.0	67.6	92.5	113.7	0.1
Total Non-Financial Liabilities	21.9	79.0	129.3	137.2	3.5
Financial Liabilities					
(i) Borrowings	0.0	0.0	0.0	0.0	9.8
(ii) Lease Liabilities	0.9	3.9	9.3	1.9	2.7
(iii) Trade Payables	58.8	42.5	57.0	33.0	38.6
Other Current Liabilities	28.3	24.7	16.7	11.5	8.6
Total Financial Liabilities	87.9	71.1	83.0	46.4	59.7
Total Equity & Liabilities	974.4	1,149.6	1,205.8	1,277.8	292.6

[#] Other Equity includes non-controlling interest

Assets (Rs. Crs)	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21
Property, Plant and Equipment	63.4	71.6	68.1	57.2	57.3
Capital Work-in-Progress	10.2	0.4	1.0	0.4	0.1
Intangibles Assets	0.1	0.1	0.1	0.1	0.4
Goodwill on Consolidation	36.1	36.1	36.1	36.1	52.7
Tax Assets (Net)	7.1	1.9	4.4	2.3	2.2
Deferred Tax Assets	11.2	0.4	1.8	0.0	0.0
Investment Property	2.3	2.4	2.6	0.0	0.0
Other Non-Current Assets	36.8	34.5	45.8	24.9	18.7
Assets classified as held for sale	0.1	0.0	0.0	0.0	0.0
Total Non-Current Assets	167.3	147.4	159.9	121.0	131.4
Inventories	110.3	115.8	180.8	113.6	77.2
Financial Assets					
(i) Investments	575.4	676.1	512.8	666.0	43.4
(ii) Trade Receivable	10.0	34.8	35.1	21.2	13.6
(iii) Cash and Cash Equivalents	12.4	31.3	31.7	13.0	12.0
(iv) Other Bank Balances	0.0	15.4	163.5	199.4	0.8
(v) Loans	9.0	8.3	8.0	9.6	8.2
Other Current Assets	89.9	120.5	114.0	134.0	6.0
Total Current Assets	807.0	1,002.2	1,045.9	1,156.8	161.2
Total Assets	974.4	1,149.6	1,205.8	1,277.8	292.6


Historical Consolidated Cash Flow Statement

Particulars (Rs. Crs)	Mar-25	Mar-24	Mar-23	Mar-22	Mar-21
Cash Flow from Operating Activities					
Profit before Tax	-203.7	-30.5	(122.3)	1,109.5	(16.4)
Adjustment for Non-Operating Items	138.1	25.8	84.0	(1,151.0)	(3.2)
Operating Profit before Working Capital Changes	-65.5	-4.6	(38.3)	(41.5)	(19.6)
Changes in Working Capital	52.7	46.6	(77.7)	(52.7)	(9.9)
Cash Generated from Operations	-12.9	42.0	(116.0)	(94.2)	(29.5)
Less: Direct Taxes paid	-4.5	-6.1	4.0	(112.9)	(1.0)
Net Cash from Operating Activities	-17.3	35.9	(112.0)	(207.1)	(30.5)
Cash Flow from Investing Activities	-1.1	-33.9	132.5	219.5	21.4
Cash Flow from Financing Activities	-0.4	-2.4	(1.8)	(11.4)	3.7
Net increase/ (decrease) in Cash & Cash Equivalent	-18.9	-0.4	18.7	1.0	(5.4)
Cash & Cash Equivalents at the beginning of the year	31.3	31.7	13.0	12.0	17.5
Cash & Cash Equivalents at the end of the year	12.4	31.3	31.7	13.0	12.0

Most Capital Efficient Player in Industry

Working Capital (No of Days)	Quarter ended			
	Mar-24	Sep-24	Mar-25	Sep-25
Inventory	35	37	35	34
Receivable	13	14	7	6
Payable	13	19	19	22
Working Capital (No of Days)	35	32	23	18
Working Capital % of Revenue	10%	9%	6%	5%
Working Capital ₹ cr	117	93	73	60

Strong Liquidity Position ₹ cr	Mar-24	Sep-24	Mar-25	Sep-25
Liquid Assets (Bank Balance, Fixed Deposit, Investment in Mutual Funds etc)	522	585	656	665



Growth acting as Catalyst for reduction in Working Capital requirement

'Being Genuine' is Our Core Value



Nothing can be more Genuine
than our Mothers' Love

BEING GENUINE

OUR CORE VALUE

We ensure that all our
products and services are
100% Genuine.

SastaSundar app
health & happiness

Retailer Shakti
Stock ka Wada, Margin Zyada

'Being Child' is Our Culture



'BEING CHILD'

IS OUR CULTURE

LIKE CHILD-
'Innovate', 'Don't Discriminate',
'Connect Emotionally' & 'Grow
Everyday'.

SastaSundar app
health & happiness

Retailer Shakti
Stock ka Wada, Margin Zyada



**Thank
You**

Company:

SastaSundar
health & happiness

SastaSundar Ventures Limited

CIN: L65993WB1989PLC047002

Mr. Pratap Singh – Company Secretary

Email Id : investors@sastasundar.com

www.sastasundarventures.com

Investor Relations Partner:



MUFG Intime India Private Limited

A part of MUFG Corporate Markets, a division of
MUFG Pension & Market Services

Ms. Prachi Ambre

prachi.ambre@in.mpms.mufg.com

+91 83559 85370

Mr. Irfan Raeen

irfan.raeen@in.mpms.mufg.com

+91 97737 78669